Marianne Sadar

Marianne Sadar is a Distinguished Scientist and Cancer Researcher who has worked at the BC Cancer Agency since 1995. Marianne has served in leadership roles internationally and was the first Canadian to chair the USA Army's Department of Defence's Programmatic Panel for Prostate Cancer Research. Marianne has also held positions as President of the Society of Basic Urologic Research (USA) and as a board member for various American and Canadian non-profit societies. In 2012, Sadar joined the University of British Columbia as a Professor of Pathology and Laboratory Medicine. In 2009, they co-founded ESSA Pharma Inc and served as its President until 2010 when they became the Chief Scientific Officer. While at ESSA Pharma Inc, Sadar developed inhibitors to the androgen N-terminal domain and successfully carried them through first-in-human clinical trials for prostate cancer patients, making it the first drug to be tested in clinical trials that directly binds to an intrinsically disordered region. Marianne remained with the company until April 2019.

Marianne Sadar holds a PhD in Biochemistry from the University of Bradford. No information regarding their years of study or any previous education is available.